Dexamethasone for ARDS, three days later gram-negative bacteremia, diffuse infiltrates, and a rash. This isn't a coincidence — it's a recognizable syndrome.
Strongyloides stercoralis is unique among human helminths in its ability to complete its full life cycle inside the host, indefinitely, through autoinfection — which is exactly what makes it dangerous decades after the original exposure.
Unlike most intestinal parasites, Strongyloides larvae can mature and reinfect the same host internally without ever leaving the body, allowing infection to persist asymptomatically for decades after the person left an endemic region. Corticosteroids suppress the Th2-mediated immune response (particularly eosinophil activity) that normally keeps autoinfection in check, allowing larvae to proliferate explosively and migrate throughout the body — hyperinfection syndrome. In disseminated disease, migrating larvae carry gut bacteria across the damaged intestinal wall directly into the bloodstream, producing polymicrobial gram-negative bacteremia and sepsis that looks like it came from nowhere.
| Finding in the vignette | Why it fits |
|---|---|
| Timing: days after starting corticosteroids | Case reports document hyperinfection triggered by even a single dose of dexamethasone (e.g., 8 mg given for fetal lung maturation), with onset as early as about a week later |
| Gram-negative bacteremia | The hallmark of dissemination — migrating larvae translocate enteric bacteria into the bloodstream; mortality in disseminated disease with bacteremia ranges 10–50% |
| Diffuse pulmonary infiltrates | Larval migration through the lungs (part of the parasite's normal life cycle) produces alveolar hemorrhage, hypersensitivity-pneumonitis-like infiltrates, and can mimic ARDS itself — a dangerous diagnostic overlap when the original indication for steroids was pulmonary disease |
| Petechial/purpuric abdominal rash ("thumbprint sign") | A described, relatively specific cutaneous finding in disseminated strongyloidiasis, from larvae migrating through subcutaneous vessels |
An institutional COVID-era protocol requiring Strongyloides screening plus empiric ivermectin before high-dose corticosteroids found that even with a formal protocol in place, only 61% of at-risk patients were actually screened, and adherence declined over time during the study period — a realistic picture of how a rare-but-lethal risk factor gets deprioritized against more visible daily ICU tasks. Risk factors worth actively asking about: birth or extended residence in an endemic region (Southeast Asia, sub-Saharan Africa, Latin America, Appalachia in the US), unexplained eosinophilia at any point in the chart, and any prior GI symptoms consistent with chronic autoinfection (intermittent abdominal pain, larva currens skin migration, unexplained cough).
The clinical vignette in the source post is an accurate representation of a real, underrecognized ICU syndrome: corticosteroids given for an unrelated indication (ARDS, COVID, autoimmune flare) can unmask latent Strongyloides infection and trigger hyperinfection or disseminated disease, presenting as unexplained gram-negative sepsis with pulmonary infiltrates and a distinctive rash. The actionable takeaway is upstream of treatment: ask about endemic-region exposure and check for unexplained eosinophilia before starting high-dose steroids in at-risk patients, since a formal screening protocol still only caught 61% of at-risk patients even when institutionally mandated.